FDA Grants Orphan Drug Status to Eisai’s Investigational Compound for Cutaneous T-Cell Lymphoma

The FDA has granted orphan drug designation to Eisai’s investigational drug E777 for the rare cutaneous t-cell lymphoma. E777 is currently being evaluated in a clinical trial that will determine its eligibility for further FDA approval.
Yahoo! Finance